References
- Naggie S , LokAS. New therapeutics for hepatitis B: the road to cure. Annu. Rev. Med., 72, 93–105 (2021).
- World Health Organization . Hepatitis B. http://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- Tang LS , CovertE, WilsonE, KottililS. Chronic hepatitis B infection: a review. JAMA, 319(17), 1802–1813 (2018).
- Suzuki F , SezakiH, HosakaTet al. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol. Res., 51(4), 503–508 (2021).
- Jiang D , WangJ, ZhaoXet al. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int., 40(1), 83–91 (2020).
- Zoulim F , DurantelD. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb. Perspect., 5(4), a021501 (2015).
- Petersen J , ThompsonAJ, LevreroM. Aiming for cure in HBV and HDV infection. J. Hepatol., 65(4), 835–848 (2016).
- Kalra A , YetiskulE, WehrleCJ, TumaF. Physiology, Liver. StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC, FL, USA (2021).
- Singh A , WeberC, VarshneyAet al. Characterization of liver specific promoters in a foamy viral vector pMD09. Acta Virol., 63(2), 162–168 (2019).
- Chen E-Q , SongX-Q, WangY-Let al. Construction of a highly-active, liver-specific transcriptional regulatory element through combination of the albumin promoter and α-fetoprotein enhancer. Plasmid, 65(2), 125–131 (2011).
- Lundstrom K . Viral vectors in gene therapy. Diseases, 6(2), 42 (2018).
- Hardee CL , Arévalo-SolizLM, HornsteinBD, ZechiedrichL. Advances in non-viral DNA vectors for gene therapy. Genes, 8(2), 65 (2017).
- Kamimura K , YokooT, AbeH, TeraiS. Gene therapy for liver cancers: current status from basic to clinics. Cancers, 11(12), 1865 (2019).
- Amir F , SiddiquiZI, FarooquiSRet al. Impact of length of replication competent genome of hepatitis B virus over the differential antigenic secretion. J. Cell. Biochem., 120(10), 17858–17871 (2019).
- Du J , MartinSM, LevineMet al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res., 16(2), 509–520 (2010).
- Zheng C , BaumBJ. Evaluation of promoters for use in tissue-specific gene delivery. Methods Mol. Biol., 434, 205–219 (2008).
- Zhang X-N , XiongW, WangJ-D, HuY-W, XiangL, YuanZ-H. siRNA-mediated inhibition of HBV replication and expression. World J. Gastroenterol., 10(20), 2967 (2004).
- Xie N , WangX, ZhangQ, LinY, LiangK, LinJ. The specific expression mediated by promoters of hepatitis B virus in hepatocarcinoma cells. Chin. Ger. J. Clin. Oncol., 5(5), 328 (2006).
- Kramer MG , BarajasM, RazquinNet al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol. Ther., 7(3), 375–385 (2003).